Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107496 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
A Phase 1 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01107496 is a Phase 1 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT01107496, a Phase 1 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD.
Interventions
- DRUG Placebo
- DRUG IR Viloxazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01107496
The ClinicalTrials.gov registry entry for NCT01107496 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01107496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01107496 about?
NCT01107496 is a clinical study titled "Evaluation of Immediate-Release Viloxazine in Adults With ADHD". This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD.
What is the current status of trial NCT01107496?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2010-06. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01107496?
The interventions under investigation include: Placebo (DRUG), IR Viloxazine (DRUG).
Who is sponsoring clinical trial NCT01107496?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.